Pharmacogenomic Effect/ADR for Acetylsalicylic acid (DBSNPE005522)

Identifier
DBSNPE005522
Drug
Acetylsalicylic acid (DB00945)
Interacting Gene/Enzyme
Cytochrome P450 2C9
Gene Name
CYP2C9
UniProt ID
P11712
Defining Change(s)
430C>Trs1799853
Allele Name
CYP2C9*2
Genotype(s)
Not Available
Type(s)
Effect Inferred
Groups
Decreased CYP2C9
Description
Poor drug metabolizer, lower dose requirements
References
  1. Rettie AE, Wienkers LC, Gonzalez FJ, Trager WF, Korzekwa KR: Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics. 1994 Feb;4(1):39-42. [PubMed:8004131]
  2. Crespi CL, Miller VP: The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase. Pharmacogenetics. 1997 Jun;7(3):203-10. [PubMed:9241660]
  3. Takahashi H, Ieiri I, Wilkinson GR, Mayo G, Kashima T, Kimura S, Otsubo K, Echizen H: 5'-Flanking region polymorphisms of CYP2C9 and their relationship to S-warfarin metabolism in white and Japanese patients. Blood. 2004 Apr 15;103(8):3055-7. Epub 2003 Dec 30. [PubMed:15070684]
  4. Sandberg M, Johansson I, Christensen M, Rane A, Eliasson E: The impact of CYP2C9 genetics and oral contraceptives on cytochrome P450 2C9 phenotype. Drug Metab Dispos. 2004 May;32(5):484-9. [PubMed:15100169]
  5. King BP, Khan TI, Aithal GP, Kamali F, Daly AK: Upstream and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolism. Pharmacogenetics. 2004 Dec;14(12):813-22. [PubMed:15608560]
  6. The Human Cytochrome P450 (CYP) Allele Nomenclature Database [Link]